Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Squamous Cell Carcinoma of Head and Neck 1Spinal Cord Neoplasms 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Optic Nerve Glioma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1Familial ependymoma 1Dendritic Cell Sarcoma, Interdigitating 1Congenital Abnormalities 1Choroid Plexus Neoplasms 1Carcinoma, Renal Cell 1Blast Crisis 1

Interventions

Cisplatin 23Radiotherapy 22Cetuximab 17Magnetic Resonance Spectroscopy 12Radiotherapy, Intensity-Modulated 10Fluorouracil 10Specimen Handling 9Platinum 91,2-diaminocyclohexaneplatinum II citrate 9pembrolizumab 8Erlotinib Hydrochloride 8Docetaxel 8Carboplatin 8Paclitaxel 7Biopsy 7Bevacizumab 7Radiation 5(225)Ac-DOTA-c(RGDyK) 5Hydroxyurea 4Gefitinib 4Radiosurgery 3Immunoglobulin G 3Disulfides 3Chemotherapy, Adjuvant 3Capecitabine 3ixabepilone 2dehydroftorafur 2atezolizumab 2aldesleukin 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Squamous Cell Carcinoma of Head and Neck × CK0238273 × Clear all
NCT00095628 2017-03-06

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Completed
21 enrolled 10 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡